Martin Auster
Stock Analyst at UBS
(2.20)
# 2,522
Out of 4,829 analysts
47
Total ratings
51.61%
Success rate
4.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $58.86 | +103.87% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $35.11 | +199.06% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $5.36 | +385.07% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $2.76 | +4,247.83% | 4 | Mar 16, 2021 | |
| GLTO Galecto | Maintains: Outperform | $725 → $300 | $2.75 | +10,828.96% | 2 | Mar 16, 2021 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $49 → $58 | $9.36 | +519.66% | 3 | Mar 10, 2021 | |
| UTHR United Therapeutics | Maintains: Outperform | $169 → $196 | $301.42 | -34.97% | 4 | Feb 22, 2021 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $62 → $98 | $0.42 | +23,106.25% | 2 | Feb 11, 2021 | |
| INSM Insmed | Maintains: Outperform | $50 → $60 | $65.08 | -7.81% | 2 | Jan 19, 2021 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $65 | $30.67 | +111.93% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $36.27 | +101.27% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $3.49 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $12.79 | +509.85% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.80 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $5.76 | +646.53% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $27.87 | +21.99% | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $8.12 | +158.62% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $19.62 | -18.45% | 1 | May 7, 2020 |
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $58.86
Upside: +103.87%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $35.11
Upside: +199.06%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $5.36
Upside: +385.07%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $2.76
Upside: +4,247.83%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $2.75
Upside: +10,828.96%
Stoke Therapeutics
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $9.36
Upside: +519.66%
United Therapeutics
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $301.42
Upside: -34.97%
ALX Oncology Holdings
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $0.42
Upside: +23,106.25%
Insmed
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $65.08
Upside: -7.81%
Scholar Rock Holding
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $30.67
Upside: +111.93%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $36.27
Upside: +101.27%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $3.49
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $12.79
Upside: +509.85%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $0.80
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $5.76
Upside: +646.53%
Jul 7, 2020
Initiates: Outperform
Price Target: $34
Current: $27.87
Upside: +21.99%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $8.12
Upside: +158.62%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $19.62
Upside: -18.45%